Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Primaquine can be used to prevent the transmission of falciparum malaria from human to mosquito. Bob Taylor and colleagues at the Mahidol Oxford Research Unit (MORU) have developed an age-based regimen for single low-dose primaquine to block the transmission of malaria in sub-Saharan Africa.

African_malaria_community_photo.jpg

Image courtesy of Speak Up Africa

The World Health Organization (WHO) recommended in 2012 to add single low-dose primaquine (SLDPQ) to standard artemisinin based combination treatments (ACTs) to block the transmission of Plasmodium falciparum malaria. The target dose of 0.25 mg base/kg body weight (15 mg in a 60 kg adult) was considered safe in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd) and SLDPQ was recommended to be given without testing for G6PDd.

Find out more (Worldwide Antimalarial Resistance Network website)